open access
Cardiac magnetic resonance characteristics of acute myocarditis occurring after mRNA-based COVID-19 vaccines immunization
Affiliations- Deptartment of Pediatric Cardiology and Congenital Heart Diseases, Medical University of Gdańsk, M. Skłodowskiej-Curie 3a, 80-210 Gdańsk, Poland
- Department of Noninvasive Cardiac Diagnostics, Medical University of Gdansk, Skłodowskiej-Curie 3a, 80-210 Gdansk, Poland
open access
Abstract
Abstract
About this articleTitle
Cardiac magnetic resonance characteristics of acute myocarditis occurring after mRNA-based COVID-19 vaccines immunization
Journal
Issue
Article type
Research Letter
Early publication date
2021-11-15
DOI
10.5603/CJ.a2021.0152
Pubmed
Authors
Jaroslaw Meyer-Szary
Magdalena Bazgier
Paulina Lubocka
Karolina Dorniak
Robert Sabiniewicz
References (10)- Habib MB, Hamamyh T, Elyas A, et al. Acute myocarditis following administration of BNT162b2 vaccine. IDCases. 2021; 25: e01197.
- Deb A, Abdelmalek J, Iwuji K, et al. Acute myocardial injury following COVID-19 vaccination: a case report and review of current evidence from vaccine adverse events reporting system database. J Prim Care Community Health. 2021; 12: 21501327211029230.
- Watkins K, Griffin G, Septaric K, et al. Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med. 2021 [Epub ahead of print].
- Baden LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5): 403–416.
- Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27): 2603–2615.
- Maron B, Udelson J, Bonow R, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. Circulation. 2015; 132(22).
- Muthukumar A, Narasimhan M, Li QZ, et al. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine. Circulation. 2021; 144(6): 487–498.
- Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-Based COVID-19 vaccines. JAMA Cardiol. 2021; 6(10): 1115–1117.
- Bajaj R, Sinclair H, Patel K, et al. Delayed-onset myocarditis following COVID-19. Lancet Resp Med. 2021; 9(4): e32–e34.
- Pfizer-BioNTech. Vaccines and Related Biological Products Advisory Committee Meeting FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine Sponsor: Pfizer and BioNTech. N Engl J Med. 2020.
